Active not recruitingOBSERVATIONAL

Evaluation of Side Effects of Mitotane

This study is about a medicine called mitotane, which is used to treat a rare type of cancer known as adrenocortical carcinoma. While mitotane is a standard treatment, doctors feel that the full range of side effects isn't always clear. This research aims to gather more information about these side effects from people who are taking the medicine. By carefully collecting this information, healthcare professionals hope to gain a better understanding of how mitotane affects patients, which can help improve care and support for those going through treatment in the future. The goal is to make sure that the experience of taking mitotane is as well understood as possible.

At a glance

Status

Active not recruiting

Sponsor

University of Wuerzburg

Enrolment target

400

Start

01 Jan 2008

Estimated completion

01 Dec 2029

Adrenocortical Carcinoma

What is this study about?

This study is focusing on a medicine named mitotane, which is a key treatment for a specific and rare type of cancer called adrenocortical carcinoma. Adrenocortical carcinoma is a cancer that starts in the outer layer of the adrenal glands, which are small glands located on top of your kidneys.

Doctors know that mitotane helps in treating this cancer, but they've noticed that not all the possible side effects of the medicine are clearly written down or fully understood. This means that while some common side effects are known, there might be others that are less common or haven't been well documented. That's why this research is so important – it's designed to collect more detailed information from people who are being treated with mitotane.

The main goal is to create a more complete picture of how mitotane affects patients. By understanding all the side effects, big and small, doctors can better prepare patients for what to expect, manage their symptoms more effectively, and ultimately improve their overall care during treatment. This study is about helping future patients by learning from those who are currently taking mitotane.

Key takeaways

The study wants to learn more about mitotane's side effects.
It's for people with adrenocortical carcinoma.
You must already be taking mitotane as treatment.
No new medicines or extra appointments are involved.
Your participation helps improve care for others.
You can stop participating at any time.

Who may be eligible?

To join this study, people need to meet a few specific requirements. First, you must have been diagnosed with adrenocortical carcinoma, which is the type of cancer this study is focused on.

Secondly, you need to be receiving mitotane as your main or only treatment for this cancer. This includes situations where mitotane is given immediately after surgery (known as adjuvant therapy) or for cancer that has spread or come back (advanced disease). The study is looking for people of any age and gender who fit these criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do you have adrenocortical carcinoma?
Are you currently being treated with mitotane?
Is mitotane your main or only medicine for this cancer?
Are you an adult or child (any age)?
Are you male or female?

Answer every question to see your result.

What does participation involve?

This study primarily involves collecting information from your medical records about your treatment with mitotane and any side effects you experience. You would continue your standard treatment as prescribed by your doctor. There are no new medications or extra procedures involved specifically for this study. The researchers will simply gather data about how you're doing while on mitotane. There are no special study visits or follow-up appointments beyond your usual medical care. The duration of your participation would depend on how long you are on mitotane treatment and when your data is collected.

Potential risks and benefits

Taking part in this study carries very little direct risk to you, as it mainly involves gathering information about your existing treatment. You won't be given any new medications or treatments. The potential benefit is that by sharing your experience, you'll be helping doctors better understand mitotane's side effects, which can improve care for future patients with adrenocortical carcinoma. You are always in control and have the right to withdraw your consent and stop participating in the study at any time without it affecting your medical care.

Locations (1)

University Hospital
Verified postcode
Würzburg, Germany

Common questions

What is adrenocortical carcinoma?

It's a rare cancer that starts in the outer layer of your adrenal glands, which are small glands above your kidneys.

What is mitotane?

Mitotane is a medicine commonly used to treat adrenocortical carcinoma.

Will I have to take a new medicine if I join?

No, this study is only about collecting information if you are already taking mitotane as part of your regular treatment.

Do I need extra hospital visits for this study?

No, you don't need any special extra visits. The study uses information from your normal medical care.

Why is this study important?

It helps doctors learn more about the side effects of mitotane, which can improve how future patients are cared for.